IMF Person
With 20 years of nonprofit experience, Michelle is passionate about philanthropy and helping organizations grow their impact. As the Director of Prospect Development for the IMF, she brings a deep understanding of fundraising strategy, campaign planning, and making the most of data to support…
Videos
Replay the FBLIVE LIVE! Join Dr. Joe Mikhael from the International Myeloma Foundation (IMF) in this in-depth Q&A session! Directly from the IMF Patient & Family Seminar in Boca Raton, Florida, Dr. Mikhael addresses your burning questions about multiple myeloma treatment.
Learn about the…
News Article
Recognizing early signs of multiple myeloma—fatigue, bone pain, and anemia—can lead to faster diagnosis and better outcomes, says IMF Chief Medica Officer Dr. Joseph Mikhael. In this interview with CURE, Dr. Mikhael discusses how new targeted therapies, immunotherapy approaches like CAR-T…
Videos
Myeloma Patient and Advocate Todd Kennedy Answers the Internet's Top Questions About Living with Myeloma
Todd Kennedy, a myeloma patient, support group leader, and advocate, answers the most-searched questions about living with multiple myeloma.
From advice for the…
News Article
The International Myeloma Foundation Announces 2nd Annual Iceland Cycling Expedition, to be Held from August 27 – September 2
Aims to raise vital funding for the iStopMM Project and Other IMF Research Initiatives
STUDIO CITY, CA, March 13, 2025 —…
News Article
In honor of Myeloma Action Month, Amgen spoke with the International Myeloma Foundation’s (IMF) Chief Medical Officer Dr. Joseph Mikhael to uncover the latest insights on myeloma care, cutting-edge therapies, and the urgent need to address…
IMF Person
Simona Grace is the Director of Development, Major Gifts at the International Myeloma Foundation, with over a decade of experience in fundraising and development across the private, public, and nonprofit sectors. She previously led major gifts at Chrysalis, building relationships with high-net-…
Videos
Join Dr. Saad Usmani, a leading myeloma specialist from Memorial Sloan Kettering Cancer Center, for an informative Facebook Live session during Myeloma Action Month.
Dr. Saad Usmani's Myeloma Action Month Q&A offers critical insights into multiple myeloma treatment, covering advances…
Videos
Smoldering Myeloma, Bone Marrow Failure & T-Cell Therapy – Dr. Joe Answers Your Myeloma Questions
IMF Chief Medical Officer Dr. Joseph Mikhael answers your questions about myeloma, covering key topics like smoldering myeloma and bone marrow failure, CAR T-cell therapy…
Videos
Download Slides
News Article
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
STUDIO CITY, CA, March 1, 2025 — Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for…
News Article
Linvoseltamab Receives Positive CHMP Opinion for Multiple Myeloma
According to this press release from Regeneron Pharmaceuticals Inc., "the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing…
News Article
STUDIO CITY, CA, Feb 27, 2025—The International Myeloma Foundation (IMF) announced today that Mr. Yelak Biru has decided to step down as President & CEO. Mr. Biru’s last day with the organization will be on February 28, 2025.
After three years of dedicated service, Mr…
Videos
Anitocabtagene autoleucel (anito-cel), a novel anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy, shows promising results in relapsed and/or refractory multiple myeloma (RRMM) patients. Initial findings from the Phase 1 and ongoing Phase 2 trials indicate high…
Videos
Elranatamab (ELRA), a bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells, showed promising results in the MagnetisMM-3 trial for relapsed or refractory multiple myeloma (RRMM). The study assessed its efficacy and safety over an extended period, including outcomes after…
Videos
The study evaluates Daratumumab (DARA) in delaying progression from high-risk smoldering multiple myeloma (SMM) to active multiple myeloma (MM). It investigates DARA's efficacy as monotherapy compared to active monitoring in delaying disease progression and its impact on progression-free survival (…
Videos
What Is the Prognosis for Multiple Myeloma? | Myeloma in a Minute or Less
What is the prognosis for someone with multiple myeloma? Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, explains how survival rates have improved dramatically.
…
Videos
ELRA, a BCMA/CD3 bispecific antibody, was evaluated in the MM-9 phase 1/2 trial for patients with relapsed/refractory multiple myeloma (RRMM). The study explored different dosing regimens and observed comparable efficacy to previous studies, with manageable safety profiles but varying rates of…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the February 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
This study investigates the efficacy and safety of lisaftoclax, a novel BCL-2 inhibitor, in combination with pomalidomide and dexamethasone (Pd) or daratumumab, lenalidomide, and dexamethasone (DRd) in patients with relapsed/refractory multiple myeloma (R/R MM) and lisaftoclax with Pd in R/R AL…
Videos
The study DREAMM-9 evaluates belantamab mafodotin (belamaf) in combination with VRd for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant (ASCT). It explores various dosing schedules and reports favorable safety profiles with notable ocular events. The study…
Videos
Q&A | Hope for High-Risk Multiple Myeloma: Latest Treatments & Life Expectancy Insights
Join Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, as he answers pressing questions from the high-risk multiple myeloma support group.…
Videos
Patient-Centric Myeloma Research at ASH 2024: Quality of Life, Exercise, Nutrition & More
IMF Chief Medical Officer Dr. Joseph Mikhael dives into patient-centric research from #ASH24, focusing on quality of life for multiple myeloma patients.
Discover groundbreaking studies on exercise,…
Videos
Myeloma Research: Late Relapse, CAR T-Cell Therapy & Bispecific Antibodies at ASH 2024
International Myeloma Foundation's Chief Medical Officer Dr. Joseph Mikhael shares the latest breakthroughs in multiple myeloma research from the ASH Annual Meeting. Learn about promising therapies for…
Videos
Belantamab & CAR T-Cell Therapy: Key ASH 2024 Updates on Early Myeloma Relapse
IMF Chief Medical Officer Dr. Joseph Mikhael breaks down major findings on early relapse from the 2024 American Society of Hematology (ASH).
IMF Chief Medical Officer Dr. Joseph…
Videos
Frontline Therapy Advances for Multiple Myeloma Patients | ASH 2024 Insights for Patients
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael breaks down the latest research on frontline therapy for multiple myeloma presented at ASH 2024.
Learn about…
Videos
This study explores the implications of measurable residual disease progression (MRD-P) in patients with newly diagnosed multiple myeloma (NDMM) treated with quadruplet therapy (QUAD) and autologous stem cell transplantation (ASCT). The research highlights how MRD-P, defined as a quantitative…
Videos
This study explores ISB 2001, a novel trispecific antibody designed to target BCMA and CD38 on myeloma cells using Ichnos’ BEAT® technology. The Phase 1 trial aims to assess safety, tolerability, pharmacokinetics, and efficacy in heavily pre-treated relapsed/refractory multiple myeloma (RRMM)…
Videos
The study investigates the efficacy and safety of MEZId, an oral CELMoD™ agent, in combination with novel therapeutic agents (TAZ, BMS-986158, TRAM) in patients with relapsed/refractory multiple myeloma (RRMM). The CA057-003 trial (NCT05372354) explores triplet combinations targeting dysregulated…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the January 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Page
Harnessing the Power of Data for the Future of the International Myeloma Foundation
Imagine being served up content that met you where you are in your patient journey. You visit the IMF website (myeloma.org) and learn what clinical trials you qualify for, or which myeloma experts can best help…
Videos
New Standard of Care for High-Risk Smoldering Multiple Myeloma: Insights from ASH 2024
IMF Chief Medical Officer Dr. Joseph Mikhael takes a deeper dive into the groundbreaking research presented at the American Society of Hematology (ASH) annual meeting, highlighting the AQUILA…
Audio
A Day in the Life of Donna Kidder | Multiple Myeloma Inspiration
In this episode of A Day in the Life Podcast, brought to you by the International Myeloma Foundation, myeloma patient Donna Kidder shares how she lives her life with the disease.
Donna Kidder…
Videos
This abstract discusses the efficacy and safety outcomes from the Phase 1b/2 STOMP trial evaluating selinexor in combination with pomalidomide and dexamethasone (SPd) for relapsed/refractory multiple myeloma (RRMM). Results show promising overall response rates (ORR), particularly in the SPd60…
Videos
In newly diagnosed multiple myeloma patients eligible for transplant, combining isatuximab with lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly increased minimal residual disease negativity compared to RVd alone. This phase III trial, GMMG-HD7, demonstrated that Isa-RVd…
Videos
The advent of bispecific antibodies like teclistamab and elranatamab has revolutionized the management of relapsed and refractory multiple myeloma (RRMM). This study from the University of Miami explores the efficacy of prophylactic tocilizumab in mitigating cytokine release syndrome (CRS)…
Videos
This study investigates the effects of a high fiber plant-based dietary (HFPBD) intervention on patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). The pilot trial included 20 participants with BMI ≥ 25, focusing on feasibility, metabolic…
Videos
Cancer and Careers: Essential Worker Protection Tips for Myeloma Patients & Care Partners
Navigating your career during cancer treatment can be overwhelming.
In this insightful discussion, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation,…
Videos
Cevostamab, a FcRH5xCD3 bispecific antibody, shows promising results in heavily treated patients with relapsed/refractory multiple myeloma (RRMM). In a Phase I study, it demonstrated dose-dependent efficacy and manageable safety profiles, particularly at the 160mg target dose level administered…
Videos
This study explores the impact of omitting 24-hour urine assessments from International Myeloma Working Group (IMWG) response criteria in multiple myeloma (MM), focusing on its effect on treatment response and prognostication. Secondary analysis of Phase 3 trial data (BMT CTN 0702) indicates…
Page
From August 29, 2024, to September 3, 2024, the International Myeloma Foundation embarked on its Inaugural Iceland Cycling Expedition. We are tremendously grateful to the 11 fundraisers who fearlessly tackled the arduous terrain of Iceland to raise funds to find a cure for multiple…
Videos
The DREAMM-7 study (NCT04246047) compared the efficacy and safety of belantamab mafodotin (BVd) versus daratumumab (DVd) in relapsed/refractory multiple myeloma (MM) patients who had received at least one prior line of therapy. BVd demonstrated superior progression-free survival (PFS) with a median…
News Article
Dear Members of the Myeloma Community,
As firefighters continue to bravely battle the wildfires across Southern California, myeloma patients and many of…
Videos
DOWNLOAD SLIDES
Videos
How Can You Safely Exercise While Living with Multiple Myeloma?
Join Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, as he explains the importance of staying active, the safest types of exercises, and what to avoid.
Exercise is essential for healthy living,…
News Article
IMF Presents Top Ten Oral and Poster Abstracts at the 2024 ASH Annual Meeting
Oral and poster abstracts co-authored by IMF President & CEO and 29-year myeloma patient Yelak Biru, IMF Chief Medical Officer Dr. Joseph Mikhael, and members of the IMF Scientific Advisory Board (SAB).…
Videos
Watch the Replay: Discover the Latest Myeloma Research at ASH — Insights for Patients & Families
In case you missed it, IMF Chief Medical Officer Dr. Joseph Mikhael and our support group leaders went live on Facebook on the evening of Monday, December 9, to discuss the key myeloma…